Melatonin and its receptor agonists work via a fundamentally different mechanism than GABA-A modulators. Melatonin is the brain's own circadian signal — secreted by the pineal gland in response to darkness, it binds MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) to entrain the circadian rhythm and promote sleep onset.
- Class
- Melatonin receptor agonists
- Mechanism
- MT1 and MT2 receptor agonism in suprachiasmatic nucleus → promotes sleep onset and entrains circadian rhythm
- Typical dose
- Ramelteon 8 mg HS; tasimelteon 20 mg HS; melatonin 0.5-5 mg HS (lower doses often more effective)
- Half-life
- Ramelteon ~1-2.6h; tasimelteon ~1.3h; melatonin ~40 min
- FDA indications
- Ramelteon: sleep onset insomnia. Tasimelteon: non-24-hour sleep-wake disorder in blind individuals. Melatonin: jet lag, shift work, sleep onset (OTC).
- Key adverse effects
- Headache, somnolence, fatigue, dizziness. No abuse liability, no withdrawal.
- Representative agents
- Ramelteon (Rozerem), tasimelteon (Hetlioz), melatonin (OTC supplement)
Useful for sleep onset (not maintenance). No abuse liability — favored over benzodiazepines/z-drugs when concerns exist. Especially useful for circadian rhythm disorders, jet lag, blind individuals with non-24h disorder, shift workers.
Ramelteon, tasimelteon, and melatonin itself are MT1/MT2 agonists. They produce sleep onset, not sleep maintenance. The patient who can't fall asleep benefits; the patient who wakes through the night does not. The effect is distinct from sedative-hypnotic suppression of sleep stages.
Ramelteon, tasimelteon, and melatonin act on the melatonin system — a circadian mechanism distinct from the GABAergic hypnotics, with a correspondingly benign safety profile.
Mechanism note: Melatonergic agents address sleep through the circadian system rather than CNS depression — modest potency but a benign safety profile that suits chronic use and circadian-rhythm disorders.
Ramelteon — Rozerem — is FDA-approved for sleep onset insomnia. 8 mg at bedtime. Non-controlled. No abuse liability. No withdrawal. Generally well-tolerated, with headache as the most common side effect. Modest effect size compared to z-drugs, but cleaner safety profile.
Tasimelteon — Hetlioz — is FDA-approved specifically for non-24-hour sleep-wake disorder in totally blind individuals, who lack the light-mediated circadian entrainment that sighted patients have. A genuinely specialized indication for a specialized population.
Melatonin — available OTC at variable doses and quality. Lower doses (0.3-1 mg) are often more effective than higher doses; this is counterintuitive but consistent with how endogenous melatonin works. Useful for jet lag (taken at destination bedtime), shift work, delayed sleep phase disorder, and adjustment to time changes. The supplement industry has produced products of variable quality — pharmaceutical-grade melatonin is preferable where available.
- Cost
- Ramelteon (Rozerem) brand ~$300+/month. Generic ramelteon limited availability ~$200/month. Melatonin OTC supplement $5-15/month. Tasimelteon (Hetlioz) ~$60,000+/year.
- Generic status
- Ramelteon generic available but limited. Melatonin OTC supplement. Tasimelteon brand-only.
- Formulary typical
- Ramelteon: variable, often PA. Tasimelteon: specialty tier, narrow indication.
- Access friction
- Ramelteon coverage variable. Tasimelteon used almost exclusively for specific non-24h sleep-wake disorder in totally blind patients.
Prescriber tip: For most patients, melatonin OTC at 0.5-3 mg is the practical answer. Quality of OTC supplements varies; recommend specific brands or pharmaceutical-grade where possible. Ramelteon for patients who need FDA-approved option without abuse liability.
For sleep onset specifically and for circadian rhythm disturbances, melatonin agonists offer a clean alternative to GABA modulators. For sleep maintenance or severe insomnia, they're insufficient. For the patient who needs long-term sleep support without controlled substance, they're a reasonable foundation.